In 2015, both the FDA and European Medicines Agency approved cobometinib, a potent, selective oral MEK1/2 inhibitor that can be taken with the B‐rapidly accelerated fibrosarcoma (BRAF) inhibitor vemurafenib for the treatment of malignant melanoma.113. This evidence concerns the gene MAP2K1 and melanoma.